Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Retatrutide is the newest weight loss medication that acts as a triple agonist at GLP-1, GIP, and glucagon receptors
Safety Position : Neither Eli Lilly nor independent investigators have endorsed higher doses
That means the first weeks may be more about reaching tolerability than reaching maximum effect
Another GLP-1 analogue, lixisenatide, was reported to prevent the acuteness of cardiovascular events in apolipoprotein E / insulin receptor substrate 2 +/ (APOE / irs2 +/ ) mice by reducing the size of AS plaques, increasing plaque stability, and promoting the conversion of macrophages to the anti-inflammatory M2 phenotype (129)
The FDA is cracking down on misleading compounded GLP-1s from telehealth companies
As with other incretin-based therapies, the most commonly reported side effects include nausea, vomiting, diarrhea and constipation, particularly during dose escalation
